Publication Name	World Journal of Hepatology
Manuscript ID	13540
Country	Taiwan

Received	2014-08-27 08:54
Peer-Review Started	2014-08-27 14:26
To Make the First Decision	2014-09-28 12:26
Return for Revision	2014-09-30 14:52
Revised	2014-11-29 11:02
Second Decision	2015-03-16 17:43
Accepted by Journal Editor-in-Chief	2015-03-17 04:30
Accepted by Executive Editor-in-Chief	2015-04-02 16:04
Articles in Press	2015-04-02 16:04
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-04-05 13:26
Typeset the Manuscript	2015-05-18 18:00
Publish the Manuscript Online	2015-06-03 12:00

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Current systemic treatment of hepatocellular carcinoma: A review of the literature
Manuscript Source	Invited Manuscript
All Author List	Kai-Wen Chen, Tzu-Ming Ou, Chin-Wen Hsu, Chi-Ting Horng, Ching-Chang Lee, Yuh-Yuan Tsai, Chi-Chang Tsai, Yi-Sheng Liou, Chen-Chieh Yang, Chao-Wen Hsueh and Wu-Hsien Kuo
Funding Agency and Grant Number
Corresponding Author	Wu-Hsien Kuo, MD, PhD, Professor, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, No.2, Zhongzheng 1st Rd., Lingya District, Kaohsiung 80284, Taiwan. wuhsienku@gmail.com
Key Words	Hepatocellular carcinoma; Transarterial chemoembolization; Sorafenib; Systemic treatment; Molecular target therapy
Core Tip	Sorafenib is a multi-targeted tyrosine kinase inhibitor that was the first systemic therapy in the world to improve the survival rate of patients with advanced hepatocellular carcinoma (HCC) in a phase Ⅲ trial. However, the overall outcomes are sometimes unsatis-factory and there is a need for second line therapies in patients with advanced HCC who still progress after the use of sorafenib. Novel systemic approaches are needed in advanced HCC.
Publish Date	2015-06-03 12:00
Citation	Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015; 7(10): 1412-1420
URL	http://www.wjgnet.com/1948-5182/full/v7/i10/1412.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i10.1412

Full Article (PDF)	WJH-7-1412.pdf
Full Article (Word)	WJH-7-1412.doc
Manuscript File	13540-Review.doc
Answering Reviewers	13540-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	13540-Conflict-of-interest statement.pdf
Copyright License Agreement	13540-Copyright assignment.pdf
Peer-review Report	13540-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	13540-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	13540-Scientific misconduct check.pdf
Scientific Editor Work List	13540-Scientific editor work list.pdf